bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
8.35
+0.09 (1.09%)
Jan 17, 2025, 4:00 PM EST - Market closed
bluebird bio Employees
bluebird bio had 375 employees as of December 31, 2023. The number of employees increased by 52 or 16.10% compared to the previous year.
Employees
375
Change (1Y)
52
Growth (1Y)
16.10%
Revenue / Employee
$141,653
Profits / Employee
-$780,867
Market Cap
81.18M
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BLUE News
- 6 weeks ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
- 6 weeks ago - Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels - Business Wire
- 6 weeks ago - bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
- 6 weeks ago - bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model - Business Wire
- 7 weeks ago - FDA investigates risk of blood cancers from bluebird bio's gene therapy - Reuters
- 2 months ago - My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 2 months ago - JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - Benzinga
- 2 months ago - bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript - Seeking Alpha